On the heels of a new warning label for its erythropoietin drugs Aranesp and Epogen, shares of Amgen Inc. dipped a little lower on more bad news. The company stopped a Phase III trial of its colorectal cancer drug Vectibix in a dual-biologic, first-line treatment regimen due to a lack of efficacy and toxicity concerns. (BioWorld Today)

On the heels of a new warning label for its erythropoietin drugs Aranesp and Epogen, shares of Amgen Inc. dipped a little lower on more bad news. The company stopped a Phase III trial of its colorectal cancer drug Vectibix in a dual-biologic, first-line treatment regimen due to a lack of efficacy and toxicity concerns. (BioWorld Today)